(482) Patients Receiving Urologic Implants Taking Sodium-Glucose Co-Transporter 2 Inhibitors, a Global, Propensity-Score Matched Analysis

Abstract Introduction Sodium-glucose co-transporter 2 inhibitors (SGLT2i) prevent the reabsorption of glucose and facilitate its excretion in urine. These medications are a newer treatment for Type Diabetes Mellitus patients have also been associated with positive cardiorenal effects. Patients taking these at hypothetical increased risk urinary tract infections given mechanism action. Objective We questioned whether SGLT2i would be an genitourinary device infection or failure. As without widespread use, we sought to utilize power multinational database generate sufficient sample size our answer. Methods TriNetX is collaborative research enterprise which collects real-time data from almost 89 million located 58 healthcare organizations across globe analyzes patient 20 years back present (2002-2022). queried all adult male undergoing Artificial Urinary Sphincter (AUS) Inflatable Penile Prosthesis (IPP). For each implant, separated into two cohorts defined by those within 1 year before and/or after surgery not this class medications. Cohorts outcomes were using Current Procedural Terminology (CPT) International Classification Diseases (ICD-10) codes. used impact Age, Race, Ethnicity, Body Mass Index, diabetes (DM) smoking history, history radiation, prostatectomy propensity score matching (PSM). Our primary outcome was need re-intervention (revision, removal, replacement surgery) any point implantation based on CPT Secondary included rate overall complication rate, including ICD-10 Analytics performed via demographic calculated Risk Ratios run June 14th, 2022 Results In total, there 8864 who underwent IPP 4272 AUS (Table 1). After PSM, 292 cohort 74 cohort. AUS, similar ages (60.6 vs 60.6 67.9 67.8 years) comorbidity profiles. The average Hemoglobin A1c level 8.0 7.4% (p<0.01) 7.9% 7.3% (p=0.13) AUS. lower (RR 0.60, p=0.02). There no difference complication. either implant second procedures both IPP. Conclusions SGLT2is may safely offered urologic implants. To knowledge, first study evaluate population. getting IPP, however rates re-intervention. remain incompletely studied but supports their use interested Disclosure Any authors act as consultant, employee shareholder industry for: Boston Scientific, Coloplast.